Chronic Graft vs. Host Disease Clinical Trial
Official title:
Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease
| NCT number | NCT00092235 |
| Other study ID # | 040281 |
| Secondary ID | 04-C-0281 |
| Status | Recruiting |
| Phase | |
| First received | |
| Last updated | |
| Start date | October 26, 2004 |
Background: - Chronic graft-versus-host disease (cGVHD) is a multi-organ alloimmune and autoimmune disorder that occurs following allogeneic hematopoietic stem cell transplantation (alloHSCT). It is characterized by immune dysregulation, immunodeficiency, impaired organ function, and decreased survival. - Each year about 8000 patients receive allogeneic hematopoietic stem cell transplant (alloHSCT) in North America and about 50% of patients who are transplanted develop cGVHD. - Chronic GVHD is also a disorder that simultaneously affects many organ systems in highly variable fashion and requires complex and coordinated medical management by multiple medical specialties. There is an urgent need for progress in understanding and effective treatments for cGVHD as it is one of the most serious complications of cancer therapy and hematopoietic stem cell transplantation. Objectives: - To establish a multidisciplinary clinic infrastructure for study of the pathogenesis and natural history of cGVHD. - To prospectively identify clinical and biological prognostic markers in patients with cGVHD - To develop clinically relevant cGVHD grading scales - To identify novel biological characteristics of cGVHD and to describe them in the context of clinical history and presentation - To identify potential clinical and biological markers of cGVHD activity - To improve understanding of the biology of cGVHD-associated graft-versus-tumor effects - To identify potential patients for cGVHD treatment protocols at the NCI and NIH Eligibility: -Patients age 1 and older referred by the primary transplant physician for the evaluation of chronic graft-versus-host disease independent of underlying diagnosis. Design: - Patient undergoes initial clinical and laboratory multispecialty work-up at the NCI cGVHD clinic. - Minimally invasive biopsies and rarely, deep tissue biopsy may be obtained to confirm the diagnosis and/or rule-out other pathologic process (in adults only). - Long tem data collection for evaluation of long-term outcomes will be conducted anually as feasible
| Status | Recruiting |
| Enrollment | 650 |
| Est. completion date | |
| Est. primary completion date | |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 1 Year and older |
| Eligibility | - INCLUSION CRITERIA: 1. Any patient age 1 and older referred by the primary transplant physician for the evaluation of chronic graft-versus-host disease independently of age or underlying diagnosis 2. Patient or the patient's legal representative is able and willing to provide consent. EXCLUSION CRITERIA: 1. Significant medical condition or any other significant circumstance that could in the PIs assessment affect the patient's ability to tolerate, comply, or complete the study 2. Patients who in the PIs assessment have a life expectancy less than 3 months. Note: Because it is not always possible to make a clear clinical distinction between acute and chronic GVHD, patients with acute GVHD are not a-priori excluded until the possibility of chronic GVHD is reliably excluded on the basis of the clinical assessments in the cGVHD clinic. 3. Pregnant women are excluded from this study because multiple tests would need to be excluded for safety of the patient and the fetus. |
| Country | Name | City | State |
|---|---|---|---|
| United States | National Institutes of Health Clinical Center | Bethesda | Maryland |
| Lead Sponsor | Collaborator |
|---|---|
| National Cancer Institute (NCI) |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | To prospectively identify candidate markers for clinical and biological prognostic factors in patients with cGVHD and develop a prognostic model | Patient evaluations resulting in collection of data via several medical specialties; data will be examined individually and against clinical outcomes. | 2 years + 3 months after protocol entry | |
| Primary | To improve our current understanding of the biology of cGVHD-associated graft-versus-tumor effects (GVT). | Studying mechanisms of how cGVHD exerts its anti-cancer effects via laboratory analysis. | ongoing | |
| Primary | To identify potential clinical and biological markers of cGVHD activity | Assessment of risk and outcome as related to molecular markers of pathogenesis and/or stage of disease. | ongoing | |
| Primary | To identify novel biological characteristics of cGVHD and to describe them in the context of clinical history and presentation | Through collection of data via several medical specialties, assess the weight of specific clinical and biological characteristics and disease severity scales for predicting major clinical outcomes. | ongoing | |
| Primary | To establish a multidisciplinary clinic infrastructure for study of pathogenesis and natural history of cGVHD | Assessment of clinical and biological characteristics of cGVHD. | ongoing | |
| Primary | To develop clinically relevant cGVHD grading scales | Develop appropriate staging as a tool for measuring responses or outcomes in clinical studies through prospective collection and analysis of data. | ongoing |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02322190 -
Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD
|
Phase 2 | |
| Available |
NCT05544032 -
Expanded Access Program for Axatilimab in Chronic Graft Versus Host Disease (GVHD)
|